Journal Mobile Options
Table of Contents
Vol. 61, No. 1, 2009
Issue release date: December 2008

Paroxysmal Non-Kinesigenic Dyskinesia Caused by the Mutation of MR-1 in a Large Polish Kindred

Friedman A. · Zakrzewska-Pniewska B. · Domitrz I. · Lee H.-Y. · Ptacek L. · Kwiecinski H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Paroxysmal non-kinesigenic dyskinesia (PNKD) is a clinical syndrome of sudden involuntary movements, mostly of dystonic type, which may be triggered by alcohol or coffee intake, stress and fatigue. The attacks of PNKD may consist of various combinations of dystonia, chorea, athetosis and balism. They can be partial and unilateral, but mostly the hyperkinetic movements are bilateral and generalized. We present a large Polish family with 7 symptomatic members of the family in 6 generations. In all affected persons, the onset of clinical symptoms was in early childhood. All male cases showed an increase in severity and frequency of the attacks with ageing, while the only living female patient noticed an improvement of PNKD during both her pregnancies and also after menopause. In addition, at the age of 55 years, she developed symptoms of Parkinson’s disease with good response to levodopa treatment.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mount LA, Reback S: Familial paroxysmal choreoathetosis. Arch Neurol Psychiatry 1940;44:841–847.

    External Resources

  2. Dermikiran M, Jankovic J: Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995;38:571–579.
  3. Lee HY, Xu Y, Huang Y, et al: The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Gen 2004;13:3161–3170.
  4. Chen DH, Matsushita M, Rainier S, et al: Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds. Arch Neurol 2005;62:597–600.
  5. Bruno MK, Lee HY, Auburger GW, Friedman A, Nielsen JE, Lang AE, et al: Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology 2007;68:1782–1789.
  6. Stefanova E, Djarmati A, Momilovi D, et al: Clinical characteristics of paroxysmal nonkinesigenic dyskinesia in Serbian family with myofibrillogenesis regulator 1 gene mutation. Mov Disord 2006;21:2010–2015.
  7. Jourdain S, Morissette M, Morin N, Di Paolo T: Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J Neuroendocrinol 2005;17:509–517.
  8. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF: Postmenopausal estrogen use affects risk for Parkinson disease. Archi Neurol 2004;61:886–888.
  9. Shulman LM: Is there a connection between estrogen and Parkinson’s disease? Parkinsonism Relat Disord 2002;8:289–295.
  10. Gamboa ET, Issacs G, Harter DH: Chorea associated with oral contraceptive therapy. Arch Neurol 1971;25:112–114.
  11. Herzog AG: Hormonal influences on spasmodic torticollis: a case report. Mov Disord 1993;8:118–119.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00